Kala Pharmaceuticals (KALA) Misses Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. STZ
4. PENG
5. NVDA
6. SPY
7. MSFT
8. SKYD
9. LEVI
10. APLD

Go back to Kala Pharmaceuticals (KALA) Misses Q3 EPS by 1c

Kala Pharmaceuticals Reports Third Quarter 2019 Financial Results

November 7, 2019 7:00 AM EST

Conference Call and Webcast Today at 8:00 a.m. ET

WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (Kala) (NASDAQ: KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY mucus-penetrating particle (MPP) Drug Delivery Technology, today reported financial results for the third quarter ended September 30, 2019.

INVELTYS demonstrated growing demand in the third quarter, with positive feedback from physicians and a continued uptick in prescriptions and market share. Additionally, we made important progress in expanding payor coverage, said Mark Iwicki, Chief Executive Officer of Kala. Our... More